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IntroductIon
Nonalcoholic fatty liver disease (NAFLD) has frequently been 
associated with obesity, type 2 diabetes mellitus (T2DM), 
hyperlipidemia, and insulin resistance, which are the main 
features of metabolic syndrome (1,2). NAFLD is an increas-
ingly recognized condition that has become the most common 
liver disorder in the developed world (1). NAFLD causes a 
wide spectrum of liver damage, ranging from simple steatosis 
(SS) to cirrhosis. In most cases, SS does not progress to a more 
severe disease, but ~20–30% of patients have histological signs 
of fibrosis and necroinflammation, indicating a presence of 
nonalcoholic steatohepatitis (NASH) (3). The pathogenesis of 
NAFLD is poorly understood and much of the current opinion 
remains hypothetical.
Obesity is considered an important risk factor, though not all 
patients with NAFLD are obese (4). In obesity, an altered secre-
tion of proteins takes place in the adipose tissue, the so-called 
adipokines, which have wide-ranging endocrine and paracrine 
effects on general metabolism (5). These adipokines are con-
sidered important determinants of obesity-related disorders 
such as insulin resistance, inflammation, and dyslipidemia (6). 
Consequently, there is growing evidence that adipokines are 
one of the causal links between obesity and NAFLD (7).
A recently identified adipokine is the retinol binding pro-
tein-4 (RBP4), the specific carrier protein of retinol (vitamin 
A) in the blood. Although the major tissue site of RBP4 syn-
thesis in the body is the liver, other sites of synthesis have been 
reported such as adipose tissues, kidney, and brain (8–10). It 
has been put forward that adipose tissue in humans, as occurs 
in mice, has the second highest level of RBP4 expression (8).
Circulating RBP4 levels have been associated with estima-
tions of adiposity and insulin resistance (11–13). Interestingly, 
we and others have reported a downregulation of RBP4 mes-
senger RNA (mRNA) in subcutaneous adipose tissue (SAT) 
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and an association of blood RBP4 with lipid parameters in 
obesity (14,15). In addition, since RBP4 was more related to 
liver fat than to abdominal fat depots, this adipokine has been 
suggested to contribute to an increase in fat accumulation in 
the liver (16).
RBP4 has scarcely been studied in patients with SS and 
NASH lesions and has had discordant results. Two studies 
using ultrasonography and magnetic spectroscopy found high 
systemic levels of RBP4 in subjects with NAFLD (17,18), but 
no correlation was found between systemic RBP4 levels and 
the histological grade of steatosis or necroinflammation in 
three biopsy-controlled studies (19–21).
To our knowledge, no study has yet analyzed simultaneously 
the levels of RBP4 in blood and its mRNA expression in sub-
cutaneous and visceral fat depots and in liver. In the present 
study, using the above approach, we aimed (i) to find out the 
gene expression profiles of RBP4 in both SAT and visceral adi-
pose tissue (VAT), and in the liver of morbidly obese (MO) 
women with or without NAFLD, (ii) to analyze if systemic 
RBP4 might be related to its expression in any of the above tis-
sues, and (iii) to study the relationships of this adipokine with 
other adipokines and with the NAFLD histological stage.
Methods and Procedures
subjects
In this study, we analyzed serum RBP4 levels in 49 Spanish women 
of European descent: four lean (BMI <25 kg/m2) and 45 MO women 
(BMI >40 kg/m2). The liver pathology was analyzed in lean controls and 
in MO women. Among the obese patients, we found 11 with normal 
liver (NL) histology and 34 with NAFLD. The diagnosis of NAFLD was 
made by the following criteria: (i) liver pathology, (ii) an intake of <10 g 
of ethanol/day, and (iii) appropriate exclusion of other liver diseases. 
Liver samples were stained with hematoxylin and eosin and Masson’s 
trichrome stains and scored by an experienced hepatopathologist using 
a modification of the methods proposed by Brunt et al. (22) and Kleiner 
et al. (23). According to the liver pathology and their BMI, patients were 
subclassified into the following groups: (i) controls: lean patients with 
NL histology (BMI <25 kg/m2, n = 4), (ii) MO with normal liver histol-
ogy (BMI >40 kg/m2, n = 11), (iii) MO with SS (BMI >40 kg/m2, micro/
macrovesicular steatosis without inflammation or fibrosis, n = 13), (iv) 
MO with NASH (BMI >40 kg/m2, Brunt grade 1–3, n = 21).
Liver biopsies were taken from MO patients if the clinical and bio-
chemical criteria in successive analyses indicated possible inflammatory 
activity in the liver. Furthermore, experts using laparoscopic techniques 
needed to have macroscopic fatty liver abnormalities observed during 
surgery. The liver biopsy was carried out only on those patients who 
fulfilled both of these criteria and/or fibrosis, which established the pres-
ence of possible inflammatory liver. The Hospital’s Pathology Service 
ensured on informed consent in order to use the liver samples of the 
control group and, once NL histology had been diagnosed, the mini-
mum excess sample was used to carry out gene expression analysis. In the 
control group, the biopsies had been taken to aid diagnosis by excluding 
any liver pathology.
Blood samples were collected with glass vacuum tubes without addi-
tives. The samples were processed and stored at −80 °C immediately.
Adipose tissue samples were collected from MO women who under-
went bariatric surgery by laparoscopic gastric bypass and from lean 
patients who underwent laparoscopic cholecystectomy for benign gall-
bladder disease or laparoscopic hiatal hernia repair. SAT biopsies were 
taken from the right hypochondrion region and VAT biopsies were taken 
from the greater epiploon region. The same specialist collected samples 
from both locations. MO and controls were age-matched. All subjects 
had a stable weight with no fluctuations of more than 2% of their body 
weight for at least 3 months before surgery. Patients were excluded from 
the study if they had an acute illness, any current evidence of acute or 
chronic inflammatory or infective diseases, an abnormal renal clearance 
or any end-stage malignant diseases.
In the MO group, 10 women had T2DM; a diagnosis based on World 
Health Organization criteria (24). None of them were receiving insulin or 
on medication likely to influence endogenous insulin levels. There were 
no patients receiving hypolipemiant treatment.
The institutional review board approved the study. All participants 
gave written informed consent for participation in medical research.
Biochemical analysis
We determined the anthropometrical and metabolic features. Body 
height and weight were measured with the patient standing in light 
clothes and shoeless. BMI was calculated as body weight divided by 
squared height (kg/m2). The subjects’ waist was measured with a soft 
tape midway between the lowest rib and the iliac crest. Laboratory stud-
ies included glucose, insulin, C-peptide, glycated hemoglobin (HbA1c), 
total cholesterol, high-density lipoprotein cholesterol, triglycerides, and 
transaminases, all of which were analyzed using a conventional auto-
mated analyzer. Insulin resistance (IR) was estimated using homeosta-
sis model assessment of IR (HOMA-IR).
RBP4 in serum samples were measured by nephelometry (Siemens 
Healthcare Care Diagnostics products GmbH, Marburg, Germany). 
Intra- and inter-assay coefficients of variation were 1.8 and 1.8%, respec-
tively. No cross-reactivity of the applied antibody is known. The assay was 
approved for in vitro diagnostic use in the United States and Europe and 
demonstrated to show excellent correlations with results obtained from 
radial immunodiffusion. Adiponectin (Linco Research, St Charles, MO), 
TNFR2 (AssayPro, St Charles, MO), and resistin (Biovendor, Modrice, 
Czech Republic) were measured in duplicate using enzyme-linked immu-
nosorbent assays following the manufacturers’ instructions.
hepG2 cell culture and treatments
HepG2 cells (ECACC cat no. 85017430) were grown in Dulbecco’s 
modified Eagle medium (DMEM BE12-604E; Lonza, Barcelona, Spain) 
supplemented with 10% fetal bovine serum (Lonza), 25 mmol/l HEPES 
(Lonza), 100 U/ml Penicillin/Streptomycin (Lonza), and 1% nonessen-
tial amino acids (Invitrogen). Cells were incubated at 37 °C in a humidi-
fied, 5% CO2-enriched atmosphere and routinely split upon reaching 
80–90% confluence. For treatments, cultures at 80–90%  confluence 
were subcultured in growth medium at a density of 4 × 105 cells/ml, and 
1 ml aliquots were seeded per well in 12-well plates (Greiner bio-one, 
Madrid, Spain). When cultures reached 80–90% confluence, growth 
medium was replaced with 1 ml of fresh growth medium without fetal 
bovine serum containing 0, 10, 25, 50, 100, 200 ng/ml tumor necro-
sis factor (TNF)-α or 0, 50, 100, 500, 1,000, 2,000 ng/ml adiponectin 
(PROSPEC, Rehout, Israel). Cultured cells were lysed and collected 
after 48 h for subsequent mRNA expression analysis.
rna isolation and real-time Pcr
Total RNA from liver and VAT or cultured cells was isolated accord-
ing to the manufacturers’ protocols RNeasy mini kit or RNeasy midi 
kit, respectively (Qiagen, Barcelona, Spain). RNA was digested with 
DNase I (RNase-Free DNase set; Qiagen). First-strand cDNA was 
synthesized using an equal amount of total RNA with High Capacity 
RNA-to-cDNA Kit (Applied Biosystems, Madrid, Spain). The real-
time quantitative PCR was carried out in a final volume of 20 µl, 
which contained 10 ng of reverse-transcribed cDNA, 10 µl of 2× 
TaqMan Fast Universal PCR Master Mix (Applied Biosystems) and 
1 µl TaqMan Assay predesigned by Applied Biosystems for the detec-
tion of RBP4, adiponectin, adiponectin receptor 2, TNF-α, resistin, 
and for GAPDH that was used as housekeeping gene. All reactions 
were carried out in triplicate in 96-well plates using the 7900HT Fast 
Real-Time PCR systems (Applied Biosystems).
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statistical analysis
All the values reported are expressed as mean ± s.d. and were analyzed 
using SPSS/PC+ for windows statistical package (v.15.0; SPSS, Chicago, 
IL). Differences between groups were calculated using the Student’s 
t-test or one-way ANOVA analysis. The strength of association between 
variables was calculated using Pearson’s method for parametric vari-
ables and Spearman’s ρ-correlation test for nonparametric contrasts. P 
values <0.05 were considered to be statistically significant.
results
Patient’s characteristics
Patients’ baseline characteristics, given in Table 1, show the 
mean and s.d. of the variables of interest. Patients were sepa-
rated into control subjects (C, n = 4, BMI <25 kg/m2), and MO 
(n = 45, BMI >40 kg/m2). MO subjects were further subclas-
sified according to the liver histology: NL (n = 11), SS (n = 
13), and NASH (n = 21). The groups were well matched for 
age. Compared with control group, MO groups displayed 
significantly higher values of fasting glucose, fasting insulin, 
HOMA-IR index, triglycerides, and low-density lipoprotein 
(LDL) cholesterol, although no differences were found between 
subgroups. We also determined the transaminase levels in MO 
women vs. lean controls. Among MO women, we found that 
those with SS or NASH showed significantly higher values 
of liver enzymes aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), and γ-glutamyltraspeptidase (GGT) 
compared with those with NL (Table 1).
Table 1 also shows the circulating levels of adiponectin, 
resistin, and TNFR2. Results indicate that the circulating lev-
els of TNFR2 were higher in the MO groups with NAFLD 
compared with NL, whereas adiponectin levels were lower in 
these groups. The analysis of the adipocytokine levels between 
SS and NASH showed that there were no differences between 
these groups.
circulating rBP4 levels
RBP4 levels were significantly higher in MO women (C: 2.5 ± 
0.2; MO: 3.3 ± 0.2; P = 0.037). Furthermore, among MO sub-
jects, those with NAFLD (SS and NASH) had higher levels of 
RBP4 compared both with controls and with those with NL 
(Table 1). Comparison between SS and NASH groups showed 
no significant differences (P = 0.237). Analysis within NASH 
patients did not show a relationship between concentrations 
of RBP4 and the degree of NASH (3.1 ± 0.8 (mild) vs. 3.3 ± 0.8 
(moderate/severe), P = 0.410).
In the MO group, we found significant associations between RBP4 
levels and triglycerides (r = 0.405, P = 0.009), AST (r = 0.440, P = 
0.010), and ALT (r = 0.440, P = 0.009). Furthermore, RBP4 in the 
circulation was negatively related with resistin levels (r = −0.398, P 
= 0.010). By contrast, RBP4 levels were not correlated with BMI (r = 
0.215, P = 0.177) or HOMA-IR (r = −0.040, P = 0.810).
In the MO cohort, only triglyceride levels appeared as an 
independent factor that explained systemic concentrations of 
table 1 Baseline characteristics of the study cohort
Group
Lean Morbid obese
Normal liver (n = 4) Normal liver (n = 11) Simple steatosis (n = 13) NASH (n = 21)
Age (years) 50.2 ± 4.1 47.2 ± 1.7 44.9 ± 3.2 47.0 ± 2.3
BMI (kg/m2) 23.1 ± 0.7 49.2 ± 1.7a 49.5 ± 2.2a 47.9 ± 1.2a
Waist (cm) 80.3 ± 7.5 134.3 ± 5.1a 127.6 ± 1.8a 134.5 ± 3.8a
Fasting glucose (mg/dl) 105.0 ± 5.3 117.8 ± 12.7 120.5 ± 7.4a 127.1 ± 8.4a
Fasting insulin (µUI/l) 8.0 ± 1.9 20.6 ± 3.4a 20.2 ± 3.2a 23.4 ± 5.4a
HbA1c (%) 4.5 ± 0.1 4.9 ± 0.2 5.7 ± 0.3 5.7 ± 0.3
HOMA-IRI 2.1 ± 0.6 6.6 ± 1.7a 5.7 ± 0.9a 8.3 ± 2.5a
Triglycerides (mg/dl) 131.0 ± 23.4 155.2 ± 12.6a 179.6 ± 21.6a 183.4 ± 16.8a
HDL-cholesterol (mg/dl) 54.4 ± 6.6 39.1 ± 2.6a 40.5 ± 2.6a 40.0 ± 1.5a
AST (IU/l) 31.7 ± 13.9 28.5 ± 8.3 58.8 ± 4.2a 48.9 ± 5.3a
ALT (IU/l) 30.7 ± 21.9 27.9 ± 5.6 64.3 ± 6.2a 50.7 ± 7.4a
GGT (IU/l) 21.1 ± 7.1 17.2 ± 2.3 31.6 ± 2.4a 29.5 ± 3.3a
Adipocytokines
 RBP4 (mg/dl) 2.5 ± 0.2 2.7 ± 0.2 3.8 ± 0.4a,b 3.3 ± 0.2a,b
 Adiponectin (µg/ml) 11.5 ± 1.7 8.8 ± 0.7 7.2 ± 1.0a 7.1 ± 0.6a
 TNFR2 (ng/ml) 3.6 ± 0.6 3.9 ± 0.5 6.0 ± 0.7a,b 5.5 ± 0.3a,b
 Resistin (ng/ml) 4.0 ± 0.5 5.0 ± 0.5 4.4 ± 0.5 4.4 ± 0.3
Data are mean ± s.d.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyltraspeptidase; HbA1c, glycated hemoglobin A1c; HDL, high-density lipoprotein; HMW 
adiponectin, high molecular weight adiponectin; HOMA-IRI, homeostasis model assessment-insulin resistance index; LDL, low-density lipoprotein; NASH, morbidly 
obese women with nonalcoholic steatohepatitis; RBP4, retinol binding protein 4; SS, morbidly obese women with simple steatosis; sTNFRII, soluble tumour necrosis 
factor receptor II.
aIndicates significant differences vs. control group (P < 0.05). bIndicates significant differences vs. morbid group with normal liver (P < 0.05).
4 www.obesityjournal.org
articles
Genetics
RBP4 (β = 0.01, P = 0.006, 95% confidence interval (CI) 0.004–
0.02). The model had a R2 of 39% and included triglycerides, 
AST, ALT, and GGT parameters.
Interestingly, when we analyzed the associations only in the 
group of women with NAFLD and after a multiple regression 
analysis, the level of triglycerides was the only parameter that 
alone could explain the RBP4 systemic concentrations (β = 
0.02, P = 0.01, 95% CI 0.003–0.02, R2 = 30%).
tissue-specific rBP4 and adiponectin gene expression
RBP4 and adiponectin mRNA SAT expression. RBP4 expres-
sion in SAT was higher in MO compared with lean subjects 
 (Figure 1a). We observed similar RBP4 gene expression 
values in SAT between the four cohorts studied: C group, 
MO with NL, with SS or NASH (not significant P value) 
(Figure 1d). Furthermore, we analyzed RBP4 expression 
between NASH-mild and NASH-moderate/severe groups. 
RBP4 was similarly expressed in both groups (2.0 ± 0.9 vs. 
3.3 ± 2.4, P = 0.35).
Adiponectin expression in SAT was significantly lower in the 
MO cohort compared with controls, but with no differences 
between MO subgroups (C: 9.5 ± 1.4 vs. MO: 4.0 ± 0.3, P = 
0.001). RBP4 and adiponectin gene expression in SAT were not 
correlated (r = −0.381, P = 0.099).
RBP4 mRNA VAT expression. Expression of RBP4 in VAT 
was significantly lower in MO women compared with the C 
group (P  = 0.001) (Figure 1b). Among MO women, values 
were similar between women with NL and with SS or NASH 
(P = 0.68), (Figure 1e). In addition, there were no differences 
between NASH-mild group and NASH-moderate/severe group 
(2.0 ± 1.0 vs. 1.6 ± 0.6, P = 0.51).
Adiponectin expression levels in VAT did not show differ-
ences between controls and MO groups (C: 5.5 ± 1.1 vs. MO: 
5.7 ± 0.4, P = 0.566). In contrast, we found significantly lower 
levels in SS and NASH subgroups compared with NL subjects 
(NL: 7.3 ± 0.5; SS: 5.6 ± 0.7, P = 0.045; NASH: 4.9 ± 0.5, P = 
0.017). Interestingly, RBP4 and adiponectin expression in VAT 
from MO were strongly correlated (r = 0.401, P = 0.025).
RBP4 mRNA liver expression. The analysis of RBP4 hepatic 
expression showed similar results in the controls to those in MO 
(P = 0.27) (Figure 1c). Within MO women, we did not find any 
differences in the expression of RBP4 between NL vs. SS and 
NASH groups (P = 0.73 and P = 0.41, respectively) (Figure 1f). 
Interestingly, NASH-mild showed higher RBP4 expression than 
NASH-moderate/severe (7.83 ± 0.91 vs. 5.02 ± 0.8, P = 0.038).
Liver adiponectin expression was lower in MO compared with 
controls (C: 2.7 × 10−4 ± 1.1 × 10−4 vs. MO: 5 × 10−5 ± 3 × 10−5, 
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Figure 1 RBP4 gene expression in (a,d) subcutaneous and (b,e) visceral adipose tissues, and in (c,f) liver respectively. *Indicates statistically 
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P = 0.029). MO subgroups displayed similar adiponectin mRNA 
levels (data not shown). In liver, RBP4 and adiponectin expression 
were strongly correlated (r = 0.530, P = 0.001) in the MO cohort.
Multivariate linear regression analysis to predict RBP4 expression 
in tissues. We performed a multivariate linear regression analysis 
to identify the best predictors of liver, subcutaneous, and visceral 
RBP4 mRNA expression in the MO cohort. We evaluated the effect 
of metabolic variables on the varaibility of the RBP4 expression 
levels in each tissue analyzed. The variables entered on the analysis 
were: fasting glucose, insulin, BMI, triglycerides, high-density lipo-
protein, and total cholesterol. The results indicated that the variables 
included were not significant predictors of the RBP4 expression in 
any of tissues studied (data not shown).
We then evaluated the effect of the mRNA expression of 
other adipocytokines on the varaibility of the RBP4 expres-
sion. The results now indicated that among the adipocytokines 
included in the model (adiponectin, TNF-α, and resistin), adi-
ponectin is the one with the highest effect on the variability of 
RBP4 expression in the last step (3rd) of the backward exclu-
sion method in VAT and liver.
In VAT the results were: β = 0.351, 95% CI 0.074–0.628, P = 
0.015. In this model, adiponectin expression explained a 29% 
of the variability RBP4 expression (Nagelkerke R2 = 0.293).
In liver the results were: β = 0.921, 95% CI 0.404–1.437, P = 
0.001. In this model, adiponectin expression explained a 40% 
of the variability RBP4 expression (Nagelkerke R2 = 0.399).
In contrast, the circulating levels of adiponectin, resistin or TNF-α 
were not relevant predictors of RBP4 expression (data not shown).
comparison between liver, Vat, and sat rBP4 gene 
expression
When the relative mRNA expression of RBP4 was analyzed in the 
three tissues, we observed that the liver had the highest expres-
sion compared with either fat depot in all the groups analyzed 
(Controls, SAT: 2.22 ± 0.24, VAT: 3.73 ± 0.36, liver: 8.85 ± 0.56, P 
= 0.023; NL, SAT: 4.17 ± 1.24, VAT: 1.72 ± 0.27, liver: 10.51 ± 2.28, 
P = 0.034; SS, SAT: 4.09 ± 1.12, VAT: 2.38 ± 0.34, liver: 7.34 ± 0.83, 
P = 0.023; NASH, SAT: 2.77 ± 0.47, VAT: 1.88 ± 0.22, liver: 6.57 
± 0.72, P = 0.043). Thus, in the four groups studied, expression in 
the liver tissue was more than double the expression in either adi-
pose tissue. In addition, in all MO groups, VAT RBP4 expression 
was lower than SAT expression, although these values were not 
statistically significant.
Circulating RBP4 levels did not correlate with its expression 
in any tissue analyzed (P value not significant).
rBP4 expression and circulating levels according 
to the presence of dM
We also compared RBP4 mRNA expression and its circulating 
levels in women with and without T2DM, because three women 
in the SS group and seven in the NASH group had T2DM.
In the SS group, the results indicate that the expression 
of RBP4 in SAT, VAT, and liver was not modified by the 
 presence of diabetes (SAT: nondiabetic: 3.3 ± 1.5 vs. diabetic: 
3.5 ± 1.0; P = 0.14, VAT: nondiabetic: 2.5 ± 1.4 vs. diabetic: 
2.2 ± 1.2; P = 0.621, liver: nondiabetic: 6.9 ± 2.0 vs. diabetic: 
6.3 ± 1.1; P = 0.93) and nor were its circulating levels (nondia-
betic: 4.1 ± 1.2 vs. diabetic: 3.5 ± 2.4; P = 0.398).
Similar results were obtained in the NASH group, subclassi-
fied according to the presence of diabetes (SAT: nondiabetic: 
2.6 ± 1.0 vs. diabetic: 2.5 ± 2.2; P = 0.481, VAT: nondiabetic: 
2.5 ± 0.9 vs. diabetic: 1.5 ± 0.6; P = 0.050, liver: nondiabetic: 
6.6 ± 2.8 vs. diabetic: 6.5 ± 2.4; P = 0.900. Circulating levels: 
nondiabetic: 3.0 ± 0.5 vs. diabetic: 3.5 ± 1.0; P = 0.469).
rBP4 expression in hepG2 cells after tnF-α or adiponectin 
exposure
We examined RBP4 expression in vitro using HepG2 cells. 
Downregulation of RBP4 expression was detected 48 h after 
exposure to TNF-α compared to controls and to adiponectin 
treatment. After the exposure to adiponectin, cells expressed 
similar levels of RBP4 than control hepatocytes (Figure 2).
dIscussIon
This is the first study to analyze circulating RBP4 levels together 
with SAT and VAT and liver gene expression in samples gath-
ered from a cohort of MO women.
In this cohort, no differences in ALT, AST, and GGT lev-
els were found between the MO with NL histology, SS, and 
NASH. In the literature, the question of whether transaminase 
levels correlate with the histological findings, particularly with 
necroinflammatory activity and the degree of fibrosis, has 
still not been answered definitively (25). In clinical practice, 
there is so far no means of differentiation reliably between SS 
and NASH solely on the basis of noninvasive (e.g., laboratory 
chemical) diagnostic tests, i.e., without liver biopsy (26,27).
The pathogenesis of NAFLD is related to IR and, thus, it is 
frequently found in individuals who have central obesity or dia-
betes. IR and excess adiposity are associated with increased lipid 
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Figure 2 Determination of RBP4 gene expression in HepG2 cells after 
the incubation with TNF-α or adiponectin. Cells either untreated (control) 
or treated with TNF-α or adiponectin for 48 h at different concentrations. 
Values are mean of three independent experiments performed in 
triplicates. *Indicates significative P values <0.05 vs. controls. GAPDH, 
glyceraldehyde 3-phosphate dehydrogenase; TNF-α, tumor necrosis 
factor-α.
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influx into the liver and increased de novo hepatic lipogenesis, 
promoting hepatic triglyceride accumulation. Some authors 
have described that HOMA-IR was associated with increased 
grades of hepatic necroinflammation (28). In our study, no dif-
ferences in HOMA-IR were found between the MO with NL 
histology, SS, and NASH. However, patients with NASH tended 
to present higher HOMA-IR values than MO with NL and SS. 
These results need to be confirmed in larger study cohorts.
Focusing on RBP4, our results indicate that its circulating lev-
els are increased in MO women, as previously reported (11,29). 
The relationship between systemic levels of RBP4 and triglyceride 
levels also confirms our previous finding in women with morbid 
obesity (29). This finding agrees with Seo et al. (17) and suggests 
a possible involvement of this adipokine with lipid metabolism. 
RBP4 is the sole transporter for retinol in the circulation, and 
retinoids are known to increase hepatic production of VLDL 
(30). Since triglycerides are the main component of VLDL lipo-
proteins, the independent association between triglycerides with 
RBP4 concentrations found could reflect the relationship between 
RBP4 and hepatic VLDL metabolism.
We then evaluated RBP4 circulating levels in relation to NAFLD 
histology. Interestingly, MO subjects with NL histology did not 
present increased levels of RBP4 compared to lean controls with 
a normal liver. In contrast, we found that circulating RBP4 lev-
els were significantly elevated in MO women with NAFLD. Our 
observation agrees with studies suggesting that RBP4 might be 
related to alterations associated with the pathogenesis of NAFLD 
(17,18). Regarding this, Stefan et al. (16) also found that circulat-
ing RBP4 correlated positively with liver fat accumulation. On the 
other hand, other studies reported lower or similar levels in nor-
mal weight or overweight subjects with NAFLD (19,20,31).
In our study, we were unable to find a relationship between 
RBP4 levels and IR, in agreement with other authors (17,19–21). 
Strikingly, we found a negative association with resistin levels, 
which agrees with Cengiz et al. (19). Although adipocyte- derived 
resistin is undisputably linked to IR in rodent models, the rel-
evance of human resistin is complicated because it is secreted by 
macrophages rather than adipocytes. Recent, growing evidence 
indicates that human resistin is an inflammatory biomarker (32). 
Therefore, the negative association between RBP4 and resistin 
might be indicating that RBP4 has a different role, rather than 
being implicated directly to IR in this cohort.
The lack of association between RBP4 circulating levels 
and obesity and insulin-resistant states has been reviewed by 
Kotnik et al. (33). It was suggested that the positive associa-
tions found previously between RBP4, obesity, IR, and T2DM 
could be the result of decreased renal clearance of RBP4 caused 
by different levels of renal insufficiency in these subjects (34). 
In order to avoid this bias, we excluded the MO women with 
abnormal renal clearance from our study group. It was also 
proposed that the imbalance between RBP4 and retinol might 
be the underlying cause for the observed association between 
RBP4 levels and systemic insulin resistance (33).
The deregulation of adipokine expression, mainly in visceral 
fat depots, suggests a link between obesity and IR. Adipokines 
released from visceral fat in IR states associated to obesity 
might augment the secretion of free fatty acids into the portal 
circulation and thus increase their accumulation in the liver as 
triglycerides (3,6,7). In our study, RBP4 mRNA expression in 
SAT and VAT appeared to be unrelated to IR or NAFLD histol-
ogy. RBP4 VAT expression was significantly lower in all groups 
of MO women. Interestingly, overall visceral RBP4 expression 
was lower than subcutaneous expression, as recently reported 
(35). On the other hand, Klöting et al. (13) found that RBP4 
expression was a marker of intra-abdominal fat mass, but these 
authors did not discriminate between normal weight and over-
weight/obese patients.
Using animal models, RBP4 has been described to be predom-
inantly synthesized in liver (36), but, to our knowledge, RBP4 
in liver from subjects with NAFLD has only been evaluated in 
a few studies (37). By immunostaining, Tönjes et al. found an 
increase in RBP4 according to the presence of SS and the grade 
of NASH (37). However, in our cohort of MO women, we found 
no significant relationships between RBP4 gene expression and 
biochemical parameters of liver function or degrees of histologi-
cal liver damage. We found that the liver had the highest expres-
sion of RBP4 in all physiological states studied, but there is a lack 
of correlation between hepatic expression and systemic levels.
In the present study, we have addressed for the first time in 
humans the circulating RBP4 levels, the gene expression of 
RBP4 in SAT and VAT and liver in parallel, in order to ana-
lyze the potential contribution of these tissues to the levels of 
RBP4 in the circulation. We did not find a correlation between 
the expression rates in the tissues analyzed and its circulating 
levels. The lack of association between RBP4 expression and its 
serum concentration might highlight the importance of con-
sidering the differences in the total production rate of adipose 
tissue-derived factors due to differences in the adiposity of the 
groups studied (38,39).
The analysis in vitro of RBP4 gene expression in hepato-
cytes indicates that TNF-α downregulates RBP4 expression. 
Furthermore, RBP4 expression in liver was lower in severe 
NASH patients. In agreement with these results, in a previous 
study from our research group, we observed in vitro that RBP4 
expression was strongly inhibited by TNF-α and lipopolysac-
charide in primary human monocytes differentiated into mac-
rophages (10). Regarding this, a negative association between 
RBP4 and proinflammatory cytokines has been described 
previously in a nonobese cohort of sepsis intensive care unit 
patients. The authors concluded that RBP4 displayed charac-
teristics of a negative acute phase reactant (40). Furthermore, 
the analysis of the multivariate analysis showed that RBP4 and 
adiponectin mRNA expression in liver and VAT are strongly 
related. Taken together, these findings, lead us to further inves-
tigate the potential anti-inflammatory role of this protein.
One of the limitations of our study is that the results cannot 
be extrapolated to other obesity groups, or men. They need to 
be confirmed using large, population-based, prospective stud-
ies that include patients of both genders with different grades 
of obesity. However, in this group we diagnosed NAFLD based 
on the analysis of liver biopsy, which is considered the “gold 
standard” method.
obesity 7
articles
Genetics
In conclusion, our study confirms in a homogeneous cohort of 
MO women that RBP4 levels are increased, and shows that MO 
subjects with NAFLD presented higher levels of RBP4 than those 
with NL histology. Furthermore, we found that, compared with 
abdominal fat depots, the liver is the tissue that predominantly 
expresses RBP4 in MO women with or without NAFLD. Finally, 
our results indicate that VAT RBP4 expression is downregulated 
in morbid obesity women, independently of hepatic condition.
Taken together, the results obtained in MO women with 
NAFLD bring up the use of a panel of adipokines including RBP4, 
as noninvasive molecular biomarkers that detect the presence of 
fatty liver in these patients. Larger studies are necessary to confirm 
these hypotheses in different obesity groups and gender.
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